| All Releases |
 |
BG Medicine, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
May 10, 2013
|
13.1 KB |
|
| |
WALTHAM, Mass., May 10, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, announced today that the company granted a stock option to Paul Sohmer, M.D., the company's newly appointed President and Chief Executive Officer, on May 10, 2013. Th...
|
|
BG Medicine Appoints Dr. Paul Sohmer as Chief Executive Officer
May 9, 2013
|
15.5 KB |
|
| |
WALTHAM, Mass., May 9, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, today announced that it has appointed Paul Sohmer, M.D., as its President & Chief Executive Officer and a member of its Board of Directors, effective immediately. Dr. ...
|
|
BG Medicine Reports 2013 First Quarter Financial Results
May 9, 2013
|
29.7 KB |
|
| |
Abbott and bioMérieux Obtain CE Mark and Launch Galectin-3 Tests in EU
BGM Galectin-3 Revenues Coupled With Operational Discipline Drive Improved Financial Results
Q1 BGM Galectin-3 test revenues grow 97% from Q1 2012
Abbott obtains CE mark and launches ARCHITECT Galectin-3 assay in Europe
bioMéri...
|
|
Trenton Health Team Adopts Novel Diagnostic Tool, BGM Galectin-3(R) Test, to Reduce Hospital Readmissions
May 8, 2013
|
16.8 KB |
|
| |
TRENTON, N.J. and WALTHAM, Mass., May 8, 2013 (GLOBE NEWSWIRE) -- The Trenton Health Team (THT) and BG Medicine (Nasdaq:BGMD) today announced that THT has adopted the BGM Galectin-3® test throughout its organization to identify patients at near term risk for heart failure rehospitalization. THT is a community health improvement collaborative t...
|
|
BG Medicine to Announce First Quarter 2013 Financial Results and Host Conference Call on Thursday, May 9, 2013
May 2, 2013
|
16.3 KB |
|
| |
WALTHAM, Mass., May 2, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced that the company will host a conference call and webcast on Thursday, May 9 at 8:30 a.m. Eastern Time to discuss its first quarter 2013 financial results. The call and webcast will follow the release of first quarter financial results before the market ...
|
|
BG Medicine Welcomes CE Mark for Galectin-3 Test
Apr 10, 2013
|
19.6 KB |
|
| |
WALTHAM, Mass., April 10, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, welcomed the announcement today that Abbott has obtained a CE Mark for the Galectin-3 assay run on the ARCHITECT immunochemistry platform.
The launch of the ARCHI...
|
|
BG Medicine Reports Fourth Quarter and Full Year 2012 Financial Results and Provides 2013 Outlook
Mar 13, 2013
|
33.3 KB |
|
| |
Q4 Revenues nearly triple from Q4 2011
Product margins increase 10% from Q4 2011
January 2013 $12.8 million public offering supplements Q4 2012 cash of $13.2 million
bioMérieux obtains CE mark for VIDAS Galectin-3 test
CardioSCORE CE mark obtained
WALTHAM, Mass., March 13, 2013 (GLOBE NEWSWIR...
|
|
BG Medicine Highlights Role of Galectin-3 Testing in Combating Hospital Readmissions at the American College of Cardiology's (ACC) 62nd Annual Scientific Session & Expo
Mar 6, 2013
|
21.7 KB |
|
| |
WALTHAM, Mass., March 6, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, today announced that company representatives and independent researchers will highlight the clinical utility of galectin-3 blood testing in assessing the prognosis o...
|
|
BG Medicine to Announce Fourth Quarter and Year-End 2012 Financial Results and Host Conference Call on Wednesday, March 13, 2013
Mar 6, 2013
|
13.4 KB |
|
| |
WALTHAM, Mass., March 6, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced that the company will host a conference call and webcast on Wednesday, March 13 at 8:30 a.m. Eastern Time to discuss its fourth quarter and year-end 2012 financial results. The call and webcast will follow the release of the fourth quarter financial re...
|
|
BG Medicine, Inc. Announces Publication of Two Studies Supporting Repeat Galectin-3 Testing in Heart Failure Patients
Feb 27, 2013
|
16.6 KB |
|
| |
WALTHAM, Mass., Feb. 27, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, announced today the publication of two studies demonstrating the clinical utility of repeated galectin-3 testing as a tool in the assessment of patients with heart f...
|
|
BG Medicine, Inc. to Present at Cowen and Company 33rd Annual Health Care Conference
Feb 27, 2013
|
13.5 KB |
|
| |
WALTHAM, Mass., Feb. 27, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) ), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that Eric Bouvier, BG Medicine's President and CEO, will be presenting at the Cowen and Company 33rd Annual Health Care Conference on March 4, 2013, at t...
|
|
BG Medicine, Inc. Announces Closing of Public Offering and Exercise of Over-Allotment Option
Jan 30, 2013
|
14.9 KB |
|
| |
WALTHAM, Mass., Jan. 30, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, today announced the closing of its previously announced public offering of 6,000,000 shares of its common stock, as well as 900,000 additional shares of its common s...
|
|
BG Medicine, Inc. Prices $12.0 Million Public Offering of Common Stock
Jan 25, 2013
|
16.4 KB |
|
| |
WALTHAM, Mass., Jan. 25, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, today announced the sale of 6,000,000 shares of its common stock in an underwritten public offering at a price to the public of $2.00 per share. The net offering pro...
|
|
BG Medicine, Inc. Announces Proposed Public Offering of Common Stock
Jan 24, 2013
|
16.2 KB |
|
| |
WALTHAM, Mass., Jan. 24, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. BG Medicine also expects to grant the underwriters a 30-da...
|
|
BG Medicine, Inc. Enters Into $12 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC
Jan 24, 2013
|
16.2 KB |
|
| |
WALTHAM, Mass., Jan. 24, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, today announced that it has entered into a common stock purchase agreement with Aspire Capital Fund, LLC. Aspire has committed to purchase up to $12 million of BG Medicine...
|
|
BG Medicine Announces Obtaining CE Mark and Launching of Automated BGM Galectin-3 Test
Jan 2, 2013
|
18.7 KB |
|
| |
WALTHAM, Mass., Jan. 2, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that the first automated version of the BGM Galectin-3® blood test has obtained a CE Mark, an important step in the company's commercial strategy.
...
|
|
BG Medicine Obtains CE Mark for CardioSCORE(TM) Test in Europe
Dec 11, 2012
|
20.6 KB |
|
| |
WALTHAM, Mass., Dec. 11, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, today announced that it has obtained a CE Mark enabling the commercial sale of the CardioSCORE™ test in the EU and other countries that recognize the CE Mark. ...
|
|
BG Medicine, Inc. to Present at 24th Annual Piper Jaffray Healthcare Conference
Nov 20, 2012
|
15.9 KB |
|
| |
WALTHAM, Mass., Nov. 20, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that Eric Bouvier, BG Medicine's President and CEO, will presenting at the 24th Annual Piper Jaffray Healthcare Conference on November 27 at 3:00 PM Easter...
|
|
BG Medicine Outlines New Commercial Strategy
Nov 13, 2012
|
21.5 KB |
|
| |
WALTHAM, Mass., Nov. 13, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, today provided an update on its new commercial strategy to speed the adoption of its cardiovascular diagnostic tests — the BGM Galectin-3® test and the CardioSC...
|
|
BG Medicine Reports Third Quarter 2012 Financial Results and Provides Business Update
Nov 13, 2012
|
38.2 KB |
|
| |
WALTHAM, Mass., Nov. 13, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today reported financial results for the third quarter ended September 30, 2012 and provided a business update.
Total revenue increased to $0.6 million in the third quarter of 2012 compared to $0.2 million in the same period in 2011. Product revenue from the B...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter
Shareholder Briefcase
Printed Materials
Email Alerts
RSS Feeds
Loading ...